News
MIMETAS and Astellas Enter into Strategic Partnership on Immuno-Oncology
March 28, 2023
Strategic Partnership Mimetas - Astellas
Read more
Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r
March 16, 2023
U.S. Patent and Trademark Office (USPTO) has issued to Modra U.S. Patent No. 11,571,408, covering the use of its oral taxane therapeutic ModraDoc006/r.
Read more
CliCr® and CliCr® derivatives are available via Iris Biotech GmbH
January 26, 2023
Iris Biotech sells CliCr® and CliCr® reagents.
Read more
Lonza Collaborates with Cristal Therapeutics and McSAF to Expand Bioconjugates Offering
January 17, 2023
- Cristal Therapeutic CliCr® technology and McSAF Inside® technology will be integrated into the Lonza Bioconjugation Toolbox...
Read more
MIMETAS Elected Most Innovative Company of the Netherlands
November 02, 2022
Mimetas is the winner of the Dutch Innovation Award 2022.
Read more
Synaffix Licenses CliCr® Chemistry from Cristal Therapeutics to Fortify Best-in-Class ADC Technology Offering
October 18, 2022
Synaffix B.V. today announces that it has signed a licensing agreement with Cristal Therapeutics to gain access to its CliCr® m...
Read more
Professor Melief to receive 2022 SITC Pedro J. Romero Award
September 08, 2022
Professor Melief to receive 2022 SITC Pedro J. Romero Award
Read more
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
September 07, 2022
MIMETAS appoints Dhaval Patel as Chair of the Board of Directors
Read more
ISA Pharmaceuticals' Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer
July 15, 2022
Recognition of commendable, longstanding dedication to the field of cancer immunotherapy
Read more
FDA Accepts Byondis' BLA for [Vic-]Trastuzumab Duocarmazine (SYD985) in HER2-Positive Metastatic Breast Cancer
July 12, 2022
Byondis acquired the technology for the development of its anti-HER2 ADC drug from Aglaia's portfolio company Syntarga in 2010.
Read more
